We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)

LumiraDx (London, UK) presented its innovative, next generation point of care diagnostics platform and seamless digital connectivity at this year’s MEDICA, the world’s largest medical trade fair, held from 15-18 November in Düsseldorf, Germany. For more than 40 years it has welcomed several thousand exhibitors from more than 50 countries. The exhibition covered all aspects of medicine and clinical care; from electromedical equipment and medical technology, physiotherapy and orthopedic technology to laboratory equipment and diagnostics.

At MEDICA 2021, LumiraDx presented the LumiraDx Platform, its innovative, disruptive solution designed to deliver lab-comparable performance to transform community care. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care.

LumiraDx offers a broad menu of lab comparable results on the LumiraDx Platform that aims to transform community care. It has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.

Related Links:
LumiraDx 

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Strongyloides Stercoralis Test
Strongyloides IgG ELISA
New
Anti-Annexin V IgG/IgM Assay
Anti-Annexin V IgG/IgM ELISA

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.